ArticleClinicoEconomics and outcomes research : CEOR2023

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece.

Gianni Ghetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.